Long-term Anticoagulation: The Case for Vorapaxar - David Moliterno, MD, FSCAI

↳ This is a section part of Moment: CRT 2016 Endovascular - Optimization of Anticoagulation for STEMI Therapy

Add this Moment to your Passport

Learn from this moment and keep it forever.
Add To Passport
$21.99
This moment is included in Simple Premium - Get started for free.
FREE with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Preview

Summary

Long-term Anticoagulation: The Case for Vorapaxar presented by David Moliterno, MD, FSCAI at CRT 2016

Add this Moment to your Passport

Learn from this moment and keep it forever.
Add To Passport
$21.99
This moment is included in Simple Premium - Get started for free.
FREE with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Target Audience

  • Interventional Cardiologists
  • Interventional Radiologists
  • Vascular Surgeons
  • Interventional Fellows

Supported by educational grants from The Medicines Company, AstraZeneca, Medicure, Inc., Boehringer Ingelheim Pharmaceuticals, Inc.

Session Name: Optimization of Anticoagulation for STEMI Therapy

Track: CRT 2016 Endovascular

Learning Objectives

Update in advances in endovascular procedures

Other Components in this Moment

Overview
Case Presentation - Toby Rogers, MD
Thrombin Inhibitors in Primary PCI: The Case for Heparin - Neal Kleiman, MD, FSCAI
Thrombin Inhibitors in Primary PCI: The Case for Bivalirudin - Roxana Mehran, MD, FACC, FSCAI
Eliminating Preloading with an Oral P2Y12: Receptor Antagonist - Gary Schaer, MD, FSCAI
Antiplatelet Therapy for STEMI – Short vs. Long Duration: The Case for Ticagrelor - David Cohen, MD, FSCAI
Antiplatelet Therapy for STEMI: The Case for Cangrelor - Gregg Stone, MD, FSCAI
Duration of Antiplatelet Therapy Post-STEMI with Which Regimen? - Sunil Rao, MD, FSCAI
Long-term Anticoagulation: The Case for Vorapaxar - David Moliterno, MD, FSCAI
Thrombus Management: The Case for High-Dose Bolus Tirofiban - Michael Lipinski, MD, PhD, FSCAI
Loading Simple Education